文献速递间质性肺疾病

进行性肺纤维化拟议标准的验证

Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

结果显示,相对FVC下降≥10%是最强预测因子,且在不满足FVC下降≥10%时,6项额外PPF标准仍与TFS降低相关。

要点

  • 相对FVC下降≥10%是非IPF ILD患者无移植生存期的最强预测因子。
  • 在不满足FVC下降≥10%时,6项额外PPF标准仍与无移植生存期降低相关。
  • 需结合生理、影像和症状恶化的复合PPF标准与单一指标预测效能相似但覆盖患者更少。

核心结论

  • 相对FVC下降≥10%及在不满足该下降时6项额外PPF标准可识别非IPF ILD患者中死亡或肺移植风险增加者。

主要发现

  • 相对FVC下降≥10%是TFS降低的最强预测因子,且在各队列、ILD亚型和治疗组中关联一致。
  • 在美国测试队列中,不满足FVC下降≥10%时10项额外PPF标准与TFS降低相关,其中6项在英国验证队列中保持关联。
  • 需组合生理、影像和症状恶化的PPF标准与单一指标预测效能相似,但覆盖患者数更少。

关键数值与推荐

  • 相对FVC下降≥10%为最强TFS预测因子,在不同队列、ILD亚型和治疗组中关联一致。
  • 不满足FVC下降≥10%时,10项额外PPF标准在美国测试队列中与TFS降低相关,6项在英国验证队列中保持关联。

临床怎么用

  • 对非IPF ILD患者,应监测相对FVC下降≥10%以识别死亡或肺移植风险增加者。
  • 在不满足FVC下降≥10%时,可参考6项验证的额外PPF标准评估预后风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Criteria for progressive pulmonary fibrosis (PPF) have been proposed, but their prognostic value beyond categorical decline in FVC remains unclear. Objectives: To determine whether proposed PPF criteria predict transplant-free survival (TFS) in patients with non-idiopathic pulmonary fibrosis (IPF) forms of interstitial lung disease (ILD). Methods: A retrospective, multicenter cohort analysis was performed. Patients with diagnoses of fibrotic connective tissue disease-associated ILD, fibrotic hypersensitivity pneumonitis, and non-IPF idiopathic interstitial pneumonia from three U.S. centers and one UK center constituted the test and validation cohorts, respectively. Cox proportional hazards regression was used to test the association between 5-year TFS and ⩾10% FVC decline, followed by 13 additional PPF criteria satisfied in the absence of ⩾10% FVC decline. Measurements and Main Results: One thousand three hundred forty-one patients met the inclusion criteria. A ⩾10% relative FVC decline was the strongest predictor of reduced TFS and showed consistent TFS association across cohorts, ILD subtypes, and treatment groups, resulting in a phenotype that closely resembled IPF. Ten additional PPF criteria satisfied in the absence of 10% relative FVC decline were also associated with reduced TFS in the U.S. test cohort, with 6 maintaining TFS associations in the UK validation cohort. Validated PPF criteria requiring a combination of physiologic, radiologic, and symptomatic worsening performed similarly to their stand-alone components but captured a smaller number of patients. Conclusions: An FVC decline of ⩾10% and six additional PPF criteria satisfied in the absence of such decline identify patients with non-IPF ILD at increased risk for death or lung transplantation.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Pugashetti JV, Adegunsoye A, Wu Z, et al. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023. PMID: 35943866. doi:10.1164/rccm.202201-0124OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。